Skip to main content

Semaglutide News

Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV

TUESDAY, April 30, 2024 – For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online...

GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer

WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...

Endoscopic Sleeve Gastroplasty Is Cost Saving Versus Semaglutide

FRIDAY, April 12, 2024 – For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA...

Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy

FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...

Ozempic, Wegovy Won't Boost Thyroid Cancer Risk: Study

WEDNESDAY, April 10, 2024 – Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight. There were concerns that...

ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes

TUESDAY, April 9, 2024 – Semaglutide leads to larger reductions in heart failure-related symptoms and physical limitations among patients with obesity-related heart failure with preserved ejection...

AANA Issues Considerations for GLP-1 Receptor Agonist Use Before Surgery

TUESDAY, March 19, 2024 – Considerations for anesthesia care in relation to use of glucagon-like peptide-1 (GLP-1) receptor agonists before surgery are addressed in a report published March 11 by...

GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV

MONDAY, March 18, 2024 – For people with HIV (PWH) with metabolic-associated steatotic liver disease (MASLD), semaglutide is associated with absolute and relative declines in intrahepatic...

Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease

Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (s...

FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions

ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...

Risk for Suicidal Ideation Not Increased With Semaglutide

TUESDAY, Jan. 9, 2024 – For individuals with overweight or obesity and type 2 diabetes, semaglutide is not associated with an increased risk for suicidal ideation compared with non-glucagon-like...

Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers

FRIDAY, Dec. 22, 2023 – Higher ultra-processed food (UPF) consumption is associated with a greater risk for head and neck cancer (HNC) and esophageal adenocarcinoma (OAC), according to a study...

Use of Noninsulin Antidiabetic Meds Increasing for T2D in Pregnancy

WEDNESDAY, Dec. 13, 2023 – Use of second-line noninsulin antidiabetic medications (ADMs) is increasing for type 2 diabetes (T2D) in pregnancy, but use is not associated with a significantly...

Risk for CRC Reduced With GLP-1RAs for Drug-Naive Patients With T2D

MONDAY, Dec. 11, 2023 – For drug-naive patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1RAs) are associated with a reduced risk for colorectal cancer (CRC)...

American Academy of Ophthalmology, Nov. 3-5

The annual meeting of the American Academy of Ophthalmology was held from Nov. 3 to 5 in San Francisco and attracted participants from around the world, including ophthalmologists, optometrists,...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Diabetes, Type 2

Related drug support groups

Ozempic, Wegovy, Rybelsus

Semaglutide patient information at Drugs.com